1. Home
  2. FNLC vs XFOR Comparison

FNLC vs XFOR Comparison

Compare FNLC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

N/A

Current Price

$27.70

Market Cap

306.9M

Sector

Finance

ML Signal

N/A

Logo X4 Pharmaceuticals Inc.

XFOR

X4 Pharmaceuticals Inc.

N/A

Current Price

$4.40

Market Cap

276.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FNLC
XFOR
Founded
1864
2014
Country
United States
United States
Employees
N/A
143
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
276.3M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FNLC
XFOR
Price
$27.70
$4.40
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$25.20
AVG Volume (30 Days)
11.0K
579.8K
Earning Date
04-22-2026
01-01-0001
Dividend Yield
5.34%
N/A
EPS Growth
26.34
N/A
EPS
3.07
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,263.94
Revenue Next Year
N/A
N/A
P/E Ratio
$9.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.11
$0.17
52 Week High
$30.33
$6.63

Technical Indicators

Market Signals
Indicator
FNLC
XFOR
Relative Strength Index (RSI) 43.90 66.78
Support Level $26.13 $3.38
Resistance Level $27.49 $4.53
Average True Range (ATR) 0.83 0.24
MACD -0.15 0.15
Stochastic Oscillator 24.17 75.79

Price Performance

Historical Comparison
FNLC
XFOR

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: